Michalis Doumas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5874473/publications.pdf

Version: 2024-02-01

318	7,151	66315	74108
papers	citations	42 h-index	75 g-index

321	321	321	9068
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias. Acta Cardiologica, 2023, 78, 519-524.	0.3	9
2	The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease. Angiology, 2022, 73, 000331972110055.	0.8	0
3	Opportunistic screening for hypertension: what does it say about the true epidemiology?. Journal of Human Hypertension, 2022, 36, 364-369.	1.0	3
4	A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 Vaccine. Angiology, 2022, 73, 87-87.	0.8	19
5	Digital Biomarkers for Supporting Transitional Care Decisions: Protocol for a Transnational Feasibility Study. JMIR Research Protocols, 2022, 11, e34573.	0.5	1
6	Colchicine for the prevention of COVID-19 â€œhardâ€•outcomes: All that glitters is not gold. European Journal of Internal Medicine, 2022, 97, 108-109.	1.0	0
7	Assessment of skin microcirculation in primary aldosteronism: impaired microvascular responses compared to essential hypertensives and normotensives. Journal of Human Hypertension, 2022, 36, 1066-1071.	1.0	4
8	Meta-Analysis Addressing the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Flow-Mediated Dilation in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2022, 165, 133-135.	0.7	2
9	Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?. International Journal of Cardiology, 2022, 348, 175.	0.8	0
10	Meta-Analysis of Randomized Controlled Trials Evaluating the Efficacy of Polymer-Free Amphilimus-Eluting Stents in Coronary Artery Disease. American Journal of Cardiology, 2022, , .	0.7	0
11	Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. American Journal of Cardiology, 2022, 167, 165-167.	0.7	1
12	Epicardial adipose tissue: does it mediate the cardioâ€protective effects of sodiumâ€“glucose coâ€transporter 2 inhibitors in patients with heart failure? Letter regarding the article â€˜Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failureâ€™. European Journal of Heart Failure, 2022, 24, 400-401.	2.9	1
13	Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients withAtype 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic. Kardiologia Polska, 2022, 80, 80-82.	0.3	0
14	Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus. Endocrinology and Metabolism, 2022, 37, 170-174.	1.3	2
15	Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106257.	0.7	4
16	Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2022, 166, 144-145.	0.7	3
17	Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. Endocrine, 2022, 76, 324-330.	1.1	4
18	â€œSGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients seriesâ€•comment. Internal and Emergency Medicine, 2022, , .	1.0	0

#	Article	IF	Citations
19	Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure Indices. American Journal of Cardiology, 2022, , .	0.7	0
20	â€œWhich one should I choose, a glucagon-like peptide-1 receptor agonist or a sodiumâ^'glucose cotransporter 2 inhibitor? Or maybe both?â€•. European Journal of Internal Medicine, 2022, 98, 125-127.	1.0	1
21	Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2022, 173, 157-158.	0.7	6
22	Impact of Primary Aldosteronism in Resistant Hypertension. Current Hypertension Reports, 2022, , 1.	1.5	2
23	Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study. Kardiologia Polska, 2022, 80, 696-698.	0.3	1
24	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease. American Journal of Cardiology, 2022, 174, 188-189.	0.7	1
25	Serum uric acid lowering mediated by glucagonâ€like peptideâ€1 receptor agonists: Emerging considerations. British Journal of Clinical Pharmacology, 2022, 88, 4239-4239.	1.1	1
26	Conservative versus aggressive blood pressure reduction: Do we have a winner?. European Journal of Internal Medicine, 2022, 101, 39-40.	1.0	0
27	Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials. Vascular Medicine, 2022, 27, 433-439.	0.8	8
28	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)â€"clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovascular Research, 2021, 117, 950-959.	1.8	33
29	Letter to the Editor: Sodiumâ€Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. Hepatology, 2021, 73, 866-866.	3.6	1
30	Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?. International Journal of Cardiology, 2021, 323, 259.	0.8	1
31	Microcirculatory function deteriorates with advancing stages of chronic kidney disease independently of arterial stiffness and atherosclerosis. Hypertension Research, 2021, 44, 179-187.	1.5	17
32	The presence of diabetes mellitus further impairs structural and functional capillary density in patients with chronic kidney disease. Microcirculation, 2021, 28, e12665.	1.0	12
33	Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria. American Journal of Cardiology, 2021, 138, 116-118.	0.7	1
34	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest. American Journal of Cardiology, 2021, 139, 134-136.	0.7	1
35	Meta-analysis Evaluating the Risk of Atrial Fibrillation With Newer Antidiabetics Across the Cardiovascular and Renal Outcome Trials. American Journal of Cardiology, 2021, 139, 139-141.	0.7	11
36	Updated metaâ€analysis assessing the risk of amputation with sodiumâ€glucose coâ€transporterâ€2 inhibitors in the hallmark cardiovascular and renal outcome trials. Diabetes, Obesity and Metabolism, 2021, 23, 1063-1065.	2.2	6

#	Article	IF	Citations
37	Meta-Analysis Assessing the Effects of Allopurinol on Left Ventricular Mass and Other Indices of Left Ventricular Remodeling as Evaluated by Cardiac Magnetic Resonance Imaging.. American Journal of Cardiology, 2021, 138, 129-132.	0.7	2
38	Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations. Acta Diabetologica, 2021, 58, 125-126.	1.2	0
39	Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis. Indian Heart Journal, 2021, 73, 132-134.	0.2	3
40	Sclerostin and cardiovascular disease: any prognostic implications?. Kardiologia Polska, 2021, 79, 99-99.	0.3	0
41	The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 Diabetes. JAMA Surgery, 2021, 156, 204.	2.2	2
42	The obesity pandemic among patients with coronary artery disease: do we have enough to tackle its progression?. Polish Archives of Internal Medicine, 2021, 131, 315-316.	0.3	0
43	The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis. Blood Pressure Monitoring, 2021, 26, 284-287.	0.4	4
44	Metaâ€analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodiumâ€glucose coâ€transporterâ€2 inhibitors: Implications for the <scp>COVIDâ€19</scp> pandemic. Diabetes, Obesity and Metabolism, 2021, 23, 1696-1700.	2.2	4
45	Coronary artery disease, arterial stiffness, and myocardial work: what is the role of diabetes in this vicious circle?. Kardiologia Polska, 2021, 79, 360-360.	0.3	0
46	Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive Review. Current Pharmaceutical Design, 2021, 27, 1289-1297.	0.9	8
47	Renal tubular transport protein regulation in primary aldosteronism: can large-scale proteomic analysis offer a new insight?. Journal of Human Hypertension, 2021, 35, 825-827.	1.0	2
48	Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 1528.	1.0	17
49	Joint ESH Excellence Centersâ€™ National Meeting on Renal Sympathetic Denervation: a Greek Expertsâ€™ Survey. Hellenic Journal of Cardiology, 2021, 62, 355-358.	0.4	1
50	Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease. Hypertension, 2021, 77, 1442-1455.	1.3	22
51	Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?. International Journal of Cardiology, 2021, 330, 228.	0.8	2
52	Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction. European Journal of Internal Medicine, 2021, 87, 100-101.	1.0	3
53	Opportunistic screening for hypertension in the general population in Greece: International Society of Hypertension May Measurement Month 2019. European Heart Journal Supplements, 2021, 23, B66-B69.	0.0	2
54	Proton pump inhibitors and the development of diabetes and its complications: a risk hidden in the shadows?. Polish Archives of Internal Medicine, 2021, 131, 590-590.	0.3	0

#	Article	IF	Citations
55	Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?. American Heart Journal, 2021, 236, 104-105.	1.2	1
56	Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?. Endocrinologia, Diabetes Y NutriciÃ“n, 2021, , .	0.1	0
57	Exercise blood pressure, cardiorespiratory fitness and mortality risk. Progress in Cardiovascular Diseases, 2021, 67, 11-17.	1.6	7
58	Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?. Kidney Medicine, 2021, 3, 674-675.	1.0	5
59	Female Sexual Dysfunction: A Problem Hidden in the Shadows. Current Pharmaceutical Design, 2021, 27, 3762-3774.	0.9	7
60	Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study. Clinical Rheumatology, 2021, 40, 4957-4968.	1.0	12
61	Patients with autoimmune chronic inflammatory diseases present increased biomarkers of thromboinflammation and endothelial dysfunction in the absence of flares and cardiovascular comorbidities. Journal of Thrombosis and Thrombolysis, 2021, , 1.	1.0	8
62	Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clinical Rheumatology, 2021, 40, 4671-4674.	1.0	21
63	Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies. Endocrinology and Metabolism, 2021, 36, 904-908.	1.3	21
64	Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH. Current Pharmaceutical Design, 2021, 27, 2537-2544.	0.9	1
65	Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?. Current Pharmaceutical Design, 2021, 27, 2714-2721.	0.9	3
66	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine, 2021, 27, 1752-1760.	15.2	353
67	Inclisiran. A New Kid on the New Block for Treating Hypercholesterolaemia. Current Vascular Pharmacology, 2021, 19, 449-450.	0.8	2
68	Hypertensive urgencies during the first wave of COVID-19 pandemic in a tertiary hospital setting: A â€œUâ€• shaped alarming curve.. Archives of Medical Science, 2021, , .	0.4	4
69	Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. Current Vascular Pharmacology, 2021, 19, 572-581.	0.8	16
70	Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. American Journal of Cardiology, 2021, 159, 143-146.	0.7	5
71	Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation. American Journal of Cardiology, 2021, 157, 150-152.	0.7	2
72	Impact of renal sympathetic denervation on cardiac magnetic resonance-derived cardiac indices in hypertensive patients â€“ A meta-analysis. Journal of Cardiology, 2021, 78, 314-321.	0.8	3

#	Article	IF	Citations
73	Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the â€œmiraculousâ€•sodium-glucose co-transporter-2 inhibitors?. Kardiologia Polska, 2021, 79, 1048-1049.	0.3	0
74	LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. International Journal of Cardiology, 2021, 345, 119-124.	0.8	19
75	Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. World Journal of Cardiology, 2021, 13, 585-592.	0.5	20
76	Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection Fraction. American Journal of Cardiology, 2021, , .	0.7	0
77	Meta-Analysis of Dedicated Heart Failure Trials Evaluating the Effect of Sacubitril/Valsartan on Major Cardiac Rhythm Disorders. American Journal of Cardiology, 2021, 161, 120-122.	0.7	0
78	Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fraction. Nefrologia, 2021, , .	0.2	0
79	Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure. American Journal of Cardiology, 2021, 161, 118-120.	0.7	2
80	Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?. Reumatologia, 2021, 59, 423-424.	0.5	0
81	Primary Aldosteronism: Novel Insights. Current Hypertension Reviews, 2020, 16, 19-23.	0.5	8
82	Hypertension in Metabolic Syndrome: Novel Insights. Current Hypertension Reviews, 2020, 16, 12-18.	0.5	42
83	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. American Journal of Cardiology, 2020, 125, 887-893.	0.7	3
84	Atrial fibrillation, arterial hypertension, and primary aldosteronism: a dangerous and unexpected trio. Journal of Hypertension, 2020, 38, 208-210.	0.3	4
85	Time to assess the effects of sodiumâ€“glucose coâ€transporterâ€2 inhibitors on the â€˜forgotten' right ventricle?. ESC Heart Failure, 2020, 7, 334-335.	1.4	3
86	Coronary angiography and acute kidney injury: The dawn for novel markers. International Journal of Cardiology, 2020, 304, 175-176.	0.8	0
87	Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?. Digestive and Liver Disease, 2020, 52, 239-240.	0.4	1
88	Coronary angiography and acute kidney injury: The dawn for novel markers. International Journal of Cardiology, 2020, 300, 119-120.	0.8	0
89	Sodiumâ€“Glucose CotransporterÂ2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions. Diabetes Therapy, 2020, 11, 3003-3005.	1.2	6
90	Updated Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Surrogate End points in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2020, 137, 130-132.	0.7	2

#	Article	IF	Citations
91	Erectile dysfunction and adherence to antihypertensive therapy: Focus on Î²-blockers. European Journal of Internal Medicine, 2020, 81, 1-6.	1.0	16
92	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. American Journal of Cardiology, 2020, 137, 133-135.	0.7	2
93	Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2020, 134, 149-152.	0.7	4
94	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. Journal of Human Hypertension, 2020, 34, 764-767.	1.0	25
95	Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and nonâ€diabetic CKD. Journal of Clinical Hypertension, 2020, 22, 2239-2249.	1.0	4
96	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1929-1936.	0.3	74
97	Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review. SN Comprehensive Clinical Medicine, 2020, 2, 1419-1429.	0.3	17
98	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. Current Hypertension Reports, 2020, 22, 90.	1.5	35
99	Sodiumâ€“glucose coâ€transporterâ€2 inhibitors and arterial stiffness: Class effect or drug effect?. Journal of Clinical Hypertension, 2020, 22, 2389-2390.	1.0	2
100	Arterial and liver stiffness in patients with non-alcoholic fatty liver disease: hitting two targets with sodium-glucose co-transporter-2 inhibitors. European Journal of Gastroenterology and Hepatology, 2020, 32, 460-461.	0.8	0
101	COVID-19: The Waterloo of governments, healthcare systems, and large health organizations. European Journal of Internal Medicine, 2020, 77, 153-155.	1.0	5
102	Update of the position paper on arterial hypertension and erectile dysfunction. Journal of Hypertension, 2020, 38, 1220-1234.	0.3	25
103	Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for sodiumâ€“glucose cotransporter-2 inhibitors?. Journal of Cardiovascular Medicine, 2020, 21, 343.	0.6	3
104	P0156SHORT-TERM BLOOD PRESSURE VARIABILITY IN DIABETIC AND NON-DIABETIC PATIENTS WITH CKD STAGE 2, 3A, 3B AND 4. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
105	Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data. International Journal of Cardiology, 2020, 316, 240-241.	0.8	2
106	P0763A COMPARATIVE STUDY OF ARTERIAL STIFFNESS AND WAVE REFLECTIONS IN DIABETIC AND NON-DIABETIC PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
107	Pharmacological Management of Type 2 Diabetes Complications. Current Vascular Pharmacology, 2020, 18, 101-103.	0.8	6
108	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodiumâ€glucose coâ€transporterâ€2 inhibitors. Journal of Clinical Hypertension, 2020, 22, 562-571.	1.0	24

#	Article	IF	Citations
109	Treatment strategies for hypertension in patients with type 1 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 1241-1252.	0.9	9
110	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and metaâ€analysis of randomized, shamâ€controlled, catheterâ€based trials. Journal of Clinical Hypertension, 2020, 22, 572-584.	1.0	29
111	Pericardial fat in type 2 diabetes: not just a biomarker, but a promising treatment target?. Acta Diabetologica, 2020, 57, 905-906.	1.2	0
112	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Current Vascular Pharmacology, 2020, 18, 172-181.	0.8	54
113	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. Current Vascular Pharmacology, 2020, 18, 125-138.	0.8	9
114	Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 347.	1.8	1
115	Recent advances in understanding and managing resistant/refractory hypertension. F1000Research, 2020, 9, 169.	0.8	14
116	Hitting two birds with one stone: the potential role of serum hypoxia-inducible factor-1Î± protein levels in obstructive sleep apneaâ€“related cardiovascular disease. Polish Archives of Internal Medicine, 2020, 130, 161-162.	0.3	1
117	Dysmetabolic Iron Overload in Metabolic Syndrome. Current Pharmaceutical Design, 2020, 26, 1019-1024.	0.9	34
118	Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis. Current Diabetes Reviews, 2020, 16, 313-326.	0.6	24
119	Postdischarge antidiabetic treatment in patients with type 2 diabetes and acute coronary syndrome: time for a change?. Kardiologia Polska, 2020, 78, 482-483.	0.3	0
120	Emerging Cardiovascular Risk Factors and Specific Patient Populations at Increased Cardiovascular Risk. Current Vascular Pharmacology, 2020, 19, 241-242.	0.8	0
121	Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. Current Vascular Pharmacology, 2020, 19, 301-312.	0.8	8
122	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. Current Vascular Pharmacology, 2020, 19, 323-342.	0.8	15
123	Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated â€œenemyâ€?. Clinical and Molecular Hepatology, 2020, 26, 582-583.	4.5	2
124	Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?. Polish Archives of Internal Medicine, 2020, 130, 922-922.	0.3	0
125	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. Current Vascular Pharmacology, 2019, 17, 425-428.	0.8	7
126	Hypertension and patients with acute coronary syndrome: Putting blood pressure levels into perspective. Journal of Clinical Hypertension, 2019, 21, 1135-1143.	1.0	19

#	Article	IF	Citations
127	Evaluation, risk stratification and management of hypertensive patients in the perioperative period. European Journal of Internal Medicine, 2019, 69, 1-7.	1.0	5
128	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. Journal of Clinical Hypertension, 2019, 21, 1578-1579.	1.0	2
129	Renal Sympathetic Denervation in Isolated Systolic Hypertension. Hypertension, 2019, 74, 255-256.	1.3	2
130	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. Journal of Sexual Medicine, 2019, 16, 1199-1211.	0.3	5
131	Mineralocorticoid Receptor Antagonists in Cardiovascular Medicine: Looking for the Forest Among the Trees. Current Pharmaceutical Design, 2019, 24, 5489-5490.	0.9	0
132	Physical Activity, Fitness, and Sexual Dysfunction. , 2019, , 373-387.		0
133	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. Expert Opinion on Drug Safety, 2019, 18, 241-251.	1.0	8
134	Now That Renal Denervation Works, How Do We Proceed?. Circulation Research, 2019, 124, 693-695.	2.0	17
135	Insomnia and hypertension: A misty landscape. Journal of Clinical Hypertension, 2019, 21, 835-837.	1.0	3
136	Orthostatic hypertension: From pathophysiology to clinical applications and therapeutic considerations. Journal of Clinical Hypertension, 2019, 21, 426-433.	1.0	47
137	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. International Journal of Cardiology: Hypertension, 2019, 3, 100022.	2.2	0
138	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 158, 107927.	1.1	16
139	Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. Current Pharmaceutical Design, 2019, 24, 3638-3646.	0.9	10
140	The VA Co-operative Studies; The First RCTs in Cardiovascular Disease â€“ A Tribute to Edward D. Freis. , 2019, , 75-88.		0
141	Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia. Current Pharmaceutical Design, 2019, 24, 3597-3598.	0.9	0
142	Metabolic syndrome: joint diagnostic criteria and links with comorbidities. Hormones, 2019, 18, 107-108.	0.9	0
143	Prehypertension, the Risk of Hypertension and Events. Updates in Hypertension and Cardiovascular Protection, 2019, , 37-55.	0.1	0
144	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2019, 24, 4587-4592.	0.9	42

#	Article	IF	Citations
145	Mineralocorticoid Receptor Antagonists in Primary Aldosteronism. Current Pharmaceutical Design, 2019, 24, 5508-5516.	0.9	8
146	SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. Current Clinical Pharmacology, 2019, 13, 261-272.	0.2	13
147	Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-NaÃ¯ve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711â€“7). Diabetes and Metabolism Journal, 2019, 43, 906.	1.8	0
148	Time to rethink the role of sodium-glucose co-transporter 2 inhibitors in the elderly. Polish Archives of Internal Medicine, 2019, 129, 939-940.	0.3	0
149	Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease. Clinical and Molecular Hepatology, 2019, 25, 331-332.	4.5	0
150	Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. Polish Archives of Internal Medicine, 2019, 129, 648-650.	0.3	0
151	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. Journal of Clinical Hypertension, 2018, 20, 589-591.	1.0	1
152	Subclinical target organ damage in primary aldosteronism. Journal of Hypertension, 2018, 36, 701.	0.3	2
153	Carotid intimaâ€media thickness as a targetâ€organ damage and treatmentâ€target: Need for a major revision?. Journal of Clinical Hypertension, 2018, 20, 255-257.	1.0	4
154	Diabetes and lipid metabolism. Hormones, 2018, 17, 61-67.	0.9	192
155	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. Journal of Clinical Hypertension, 2018, 20, 634-636.	1.0	2
156	The potential role of statins in treating liver disease. Expert Review of Gastroenterology and Hepatology, 2018, 12, 331-339.	1.4	17
157	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. Journal of Clinical Hypertension, 2018, 20, 469-471.	1.0	2
158	Sacubitril/valsartan instead of reninâ€angiotensin system inhibition alone: A step forward in resistant hypertension. Journal of Clinical Hypertension, 2018, 20, 65-68.	1.0	9
159	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. Journal of Clinical Hypertension, 2018, 20, 942-948.	1.0	10
160	What is the role of statins in the elderly population?. Expert Review of Clinical Pharmacology, 2018, 11, 329-331.	1.3	1
161	Psoriasis and Cardiovascular Disease: Two Sides of the Same Coin?. Angiology, 2018, 69, 5-9.	0.8	3
162	Antihypertensive drug treatment: the realâ€life challenge. Journal of Clinical Hypertension, 2018, 20, 115-117.	1.0	1

#	Article	IF	Citations
163	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. Open Cardiovascular Medicine Journal, 2018, 12, 29-40.	0.6	19
164	Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 120-126.	0.2	5
165	Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 83-85.	0.2	0
166	Early Vascular Aging Risk Assessment From Ambulatory Blood Pressure Monitoring: The Early Vascular Aging Ambulatory Score. American Journal of Hypertension, 2018, 31, 1197-1204.	1.0	13
167	Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality. Current Vascular Pharmacology, 2018, 16, 206-208.	0.8	1
168	Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis. Current Vascular Pharmacology, 2018, 16, 104-106.	0.8	5
169	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	1.3	94
170	Erectile dysfunction: definition and size of the problem. , 2018, , .		1
171	Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. Current Pharmaceutical Design, 2018, 24, 1879-1886.	0.9	16
172	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Current Vascular Pharmacology, 2018, 16, 130-142.	0.8	54
173	The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?. Current Vascular Pharmacology, 2018, 16, 254-268.	0.8	13
174	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Current Vascular Pharmacology, 2018, 16, 246-253.	0.8	69
175	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. Current Vascular Pharmacology, 2018, 16, 276-288.	0.8	4
176	Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension. Current Vascular Pharmacology, 2018, 16, 393-400.	0.8	9
177	Lipid association of India (LAI) expert consensus statement: part 2, specific patient categories. Clinical Lipidology, 2018, 13, 1-3.	0.4	1
178	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: Clinical and Experimental, 2017, 71, 17-32.	1.5	208
179	Left ventricular hypertrophy in athletes and hypertensive patients. Journal of Clinical Hypertension, 2017, 19, 413-417.	1.0	48
180	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 249-253.	0.9	45

#	Article	IF	Citations
181	Obstructive sleep apnea, hypertension, and fibrin clot properties. Journal of Hypertension, 2017, 35, 950-952.	0.3	0
182	Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension. Journal of Hypertension, 2017, 35, 1750-1757.	0.3	11
183	Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 39.	0.4	6
184	Hematocrit and Stroke: A Forgotten and Neglected Link?. Seminars in Thrombosis and Hemostasis, 2017, 43, 591-598.	1.5	15
185	Blood pressure and cardiovascular outcomes: a closer look. Lancet, The, 2017, 389, 1295-1296.	6.3	1
186	Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. American Journal of Nephrology, 2017, 45, 136-145.	1.4	13
187	Abnormal blood pressure dipping in diabetic kidney disease: A blackâ€race nightmare?. Journal of Clinical Hypertension, 2017, 19, 1336-1338.	1.0	3
188	The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology, 2017, 10, 1251-1261.	1.3	9
189	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. American Journal of Medicine, 2017, 130, 1465.e27-1465.e39.	0.6	17
190	Impact of Cardiorespiratory Fitness on Mortality in Black Male Veterans With Resistant Systemic Hypertension. American Journal of Cardiology, 2017, 120, 1568-1571.	0.7	7
191	Testosterone Replacement Therapy and Cardiovascular Riskâ€"A Closer Look at Additional Parameters. JAMA Internal Medicine, 2017, 177, 1393.	2.6	2
192	Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients?. Journal of Clinical Hypertension, 2017, 19, 798-800.	1.0	6
193	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care, 2017, 40, 1401-1408.	4.3	68
194	Time in Therapeutic Range, as a Determinant of Allâ€Cause Mortality in Patients With Hypertension. Journal of the American Heart Association, 2017, 6, .	1.6	50
195	Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?. Current Vascular Pharmacology, 2017, 16, 30-43.	0.8	6
196	Clinical Value of Measuring the Renin/Aldosterone Levels: Optimising the Management of Uncontrolled/Resistant Hypertension. Current Vascular Pharmacology, 2017, 16, 10-14.	0.8	8
197	Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?. Current Vascular Pharmacology, 2017, 16, 66-69.	0.8	7
198	SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. Current Pharmaceutical Design, 2017, 23, 1510-1521.	0.9	15

#	Article	IF	Citations
199	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. Current Pharmaceutical Design, 2017, 23, 1477-1483.	0.9	6
200	Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun. Current Pharmaceutical Design, 2017, 23, 1540-1550.	0.9	14
201	Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?. Open Hypertension Journal, 2017, 9, 1-5.	0.8	0
202	Erectile Function in Cardiovascular Disease and Hypertension: the Role of Nebivolol. Journal of Hypertension: Open Access, 2016, 05, .	0.2	5
203	Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. American Journal of Nephrology, 2016, 43, 271-280.	1.4	43
204	Selecting Optimum Antihypertensive Therapy. , 2016, , 217-247.		0
205	Renal Denervation: A Historical Perspective. Updates in Hypertension and Cardiovascular Protection, 2016, , 201-213.	0.1	0
206	Approach to Erectile Dysfunction in Patients with Hypertension and Coronary Artery Disease. , 2016, , 309-327.		2
207	Fitness: The â€œSecretâ€•of Vascular Youth. Journal of Clinical Hypertension, 2016, 18, 290-291.	1.0	0
208	Primary Aldosteronism: A Field on the Move. Updates in Hypertension and Cardiovascular Protection, 2016, , 29-55.	0.1	1
209	Renal Sympathetic Denervation: Hibernation or Resurrection?. Cardiology, 2016, 135, 87-97.	0.6	6
210	Depression in hypertensive patients. Journal of Hypertension, 2016, 34, 1441.	0.3	1
211	Important practice lessons from the SPRINT study beyond the blood pressure goal: all well known and now confirmed. Journal of the American Society of Hypertension, 2016, 10, 613-617.	2.3	6
212	PATHWAY-2: spironolactone for resistant hypertension. Lancet, The, 2016, 387, 1371-1372.	6.3	0
213	Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action. Indian Heart Journal, 2016, 68, 596-598.	0.2	2
214	Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?. American Journal of Hypertension, 2016, 29, 662-662.	1.0	6
215	Discontinuation of Antihypertensive Treatment in Elderly Patients and Cognitive Function. JAMA Internal Medicine, 2016, 176, 409.	2.6	0
216	Lipids, Statins and Heart Failure: An Update. Current Pharmaceutical Design, 2016, 22, 4796-4806.	0.9	23

#	Article	IF	Citations
217	Current challenges in antihypertensive treatment in the elderly. Polish Archives of Internal Medicine, 2016, 126, 540-551.	0.3	0
218	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. Clinical Lipidology, 2016, 11, 2-5.	0.4	3
219	Exaggerated Blood Pressure Response to Exercise: Will It Ever Be Ready for Prime Time?. Journal of Clinical Hypertension, 2015, 17, 845-847.	1.0	2
220	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World Journal of Gastroenterology, 2015, 21, 6820-6834.	1.4	120
221	Erectile dysfunction in chronic kidney disease: From pathophysiology to management. World Journal of Nephrology, 2015, 4, 379.	0.8	32
222	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World Journal of Gastroenterology, 2015, 21, 7860.	1.4	130
223	Screening for Primary Aldosteronism: Whom and How?. Journal of Clinical Hypertension, 2015, 17, 547-548.	1.0	7
224	Transcatheter Renal Sympathetic Denervation: Chasing a Chimera or a Matter of Technological Improvements?. Cardiology, 2015, 131, 186-188.	0.6	4
225	Hyperuricemia as a risk factor for cardiovascular disease. Expert Review of Cardiovascular Therapy, 2015, 13, 19-20.	0.6	19
226	Arterial Stiffness and Emerging Biomarkers. Angiology, 2015, 66, 901-903.	0.8	12
227	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International, 2015, 87, 649-659.	2.6	158
228	Recent advances in the management of resistant hypertension. F1000prime Reports, 2015, 7, 03.	5.9	3
229	PDE-5 Inhibitors: Clinical Points. Current Drug Targets, 2015, 16, 420-426.	1.0	24
230	Sympathetic Renal Denervation Using the EnligHTN Multi-electrode Ablation System: The St Jude Experience. , 2015, , 69-79.		0
231	Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation. Current Vascular Pharmacology, 2014, 12, 55-62.	0.8	10
232	Non-interventional management of resistant hypertension. World Journal of Cardiology, 2014, 6, 1080.	0.5	5
233	Carotid Baroreceptor Stimulation: A Promising Approach for the Management of Resistant Hypertension and Heart Failure. Current Vascular Pharmacology, 2014, 12, 30-37.	0.8	16
234	Editorial (Thematic Issue: Interventional Management of Hypertension and Cardiovascular Disease: The) Tj ETQq0 0 0 rgBT /Overlock 10	0.8	4

#	Article	IF	Citations
235	Management of erectile dysfunction in hypertension: Tips and tricks. World Journal of Cardiology, 2014, 6, 908.	0.5	46
236	Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit. Expert Review of Cardiovascular Therapy, 2014, 12, 295-296.	0.6	1
237	Renal Nerve Ablation for Resistant Hypertension: The Dust Has Not Yet Settled. Journal of Clinical Hypertension, 2014, 16, 399-400.	1.0	3
238	Renal Denervation. Angiology, 2014, 65, 760-768.	0.8	3
239	Antihypertensive Therapy After Acute Ischemic Stroke. JAMA - Journal of the American Medical Association, 2014, 311, 2333.	3.8	1
240	Statin Therapy, Fitness, and Mortality Risk in Middle-Aged Hypertensive Male Veterans. American Journal of Hypertension, 2014, 27, 422-430.	1.0	20
241	Renal Denervation and Symplicity HTN-3. Circulation Research, 2014, 115, 211-214.	2.0	49
242	Platelet Activation in Essential Hypertension During Exercise: Pre- and Post-Treatment Changes With an Angiotensin II Receptor Blocker. American Journal of Hypertension, 2014, 27, 571-578.	1.0	12
243	Renal Nerve Ablation for Resistant Hypertension. Circulation, 2014, 129, 1440-1451.	1.6	47
244	Exercise Capacity and All-Cause Mortality in Male Veterans With Hypertension Aged â‰¥70 Years. Hypertension, 2014, 64, 30-35.	1.3	56
245	Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity. Journal of Hypertension, 2014, 32, 415-422.	0.3	70
246	First-degree atrioventricular block is associated with advanced atrioventricular block, atrial fibrillation and left ventricular dysfunction in patients with hypertension. Journal of Hypertension, 2014, 32, 1115-1120.	0.3	9
247	Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy. Current Pharmaceutical Design, 2014, 20, 6339-6349.	0.9	17
248	To Stent or Not to Stent? This is the Renal Artery Stenosis Question. Open Hypertension Journal, 2014, 6, 1-2.	0.8	0
249	CONGRESS COVERAGE: Antihypertensive Therapy in Acute Ischemic Stroke: Lost in the Mist. Open Hypertension Journal, 2014, 6, 10-11.	0.8	0
250	CONGRESS COVERAGE: Renal Sympathetic Denervation for Resistant Hypertension: Symplicity HTN-3 and the Power of Placebo. Open Hypertension Journal, 2014, 6, 18-19.	0.8	0
251	Macro and microcirculation damage and incident hypertension. Journal of Hypertension, 2014, 32, 1154.	0.3	2
252	EDITORIAL-Blood Pressure as a Risk Factor of Global Disease Burden and its Association with Lifetime Risks of Different Manifestations of Cardiovascular Disease. Open Hypertension Journal, 2014, 6, 32-34.	0.8	0

#	Article	IF	Citations
253	Gender Differences in Hypertension: Myths and Reality. Current Hypertension Reports, 2013, 15, 321-330.	1.5	110
254	The impact of frequently encountered cardiovascular risk factors on sexual dysfunction in rheumatic disorders. Andrology, 2013, 1, 556-562.	1.9	14
255	Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet, The, 2013, 381, 394-399.	6.3	179
256	Statin and exercise prescription â€“ Authors' reply. Lancet, The, 2013, 381, 1622-1623.	6.3	1
257	Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Current Medical Research and Opinion, 2013, 29, 1263-1274.	0.9	77
258	Heart Rate at Rest, Exercise Capacity, and Mortality Risk in Veterans. American Journal of Cardiology, 2013, 112, 1605-1609.	0.7	18
259	The unappreciated importance of blood pressure in recent and older atrial fibrillation trials. Journal of Hypertension, 2013, 31, 2109-2117.	0.3	19
260	Divergent Retinal Vascular Abnormalities in Normotensive Persons and Patients With Never-Treated, Masked, White Coat Hypertension. American Journal of Hypertension, 2013, 26, 318-325.	1.0	49
261	Masked Hypertension in Untreated and Treated Patients With Diabetes Mellitus. Hypertension, 2013, 62, e21.	1.3	1
262	Platelet activation during exercise is not attenuated by inhibition of the reninâ€“angiotensin system. Journal of Hypertension, 2013, 31, 2103.	0.3	1
263	Effects of hypertension and antihypertensive therapy on sexual function in the elderly. Journal of Hypertension, 2013, 31, 1917-1918.	0.3	3
264	Editorial: Do We Have Effective Means to Treat Arterial Stiffness and High Central Aortic Blood Pressure in Patients with and without Hypertension?. Open Hypertension Journal, 2013, 5, 56-57.	0.8	2
265	LETTER TO THE EDITOR: Pomegranate Juice is Useful for the Management of Hypertension and the Improvement of Cardiovascular Health. Open Hypertension Journal, 2013, 5, 41-42.	0.8	1
266	EDITORIAL: No-Pharmacological Intervention: Pomegranate Juice for the Management of Hypertension and the Improvement of Cardiovascular Health. Open Hypertension Journal, 2013, 5, 23-26.	0.8	1
267	LETTER TO THE EDITOR Pay-for-performance Versus a Budget-Restrictive System for the Management of Dyslipidemia. Should this Approach also be Applied in Hypertension?. Open Hypertension Journal, 2013, 5, 32-34.	0.8	2
268	Surgical Management of Primary Aldosteronism. Not Everything that Shines is Gold. Clinical and Experimental Hypertension, 2012, 34, 53-56.	0.5	3
269	Leiomyosarcoma of Renal Vein, Initially Resembling Pheochromocytoma. Clinical and Experimental Hypertension, 2012, 34, 429-431.	0.5	7
270	Body mass index, exercise capacity, and mortality risk in male veterans with hypertension. American Journal of Hypertension, 2012, 25, 444-450.	1.0	36

#	Article	IF	Citations
271	Letter by Triantafyllou et al Regarding Article, â€œMild Retinopathy Is a Risk Factor for Cardiovascular Mortality in Japanese With and Without Hypertension: The Ibaraki Prefectural Health Studyâ€. Circulation, 2012, 126, e12; author reply e14.	1.6	2
272	Cardiovascular Risk in Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2012, 18, 422-430.	0.5	56
273	BMIâ€“Mortality Paradox and Fitness in African American and Caucasian Men With Type 2 Diabetes. Diabetes Care, 2012, 35, 1021-1027.	4.3	92
274	Heart rate recovery, exercise capacity, and mortality risk in male veterans. European Journal of Preventive Cardiology, 2012, 19, 177-184.	0.8	27
275	Management of Erectile Dysfunction: Do Not Forget Hypertension. Archives of Internal Medicine, 2012, 172, 597-8; discussion 598.	4.3	5
276	Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension. Journal of Hypertension, 2012, 30, 874-876.	0.3	49
277	Effects of antihypertensive therapy on female sexual dysfunction. Journal of Hypertension, 2012, 30, 1263-1264.	0.3	2
278	Exercise Capacity and Progression From Prehypertension to Hypertension. Hypertension, 2012, 60, 333-338.	1.3	98
279	Carotid Baroreceptor Activation for the Treatment of Resistant Hypertension and Heart Failure. Current Hypertension Reports, 2012, 14, 238-246.	1.5	26
280	Antihypertensive Treatment and Sexual Dysfunction. Current Hypertension Reports, 2012, 14, 285-292.	1.5	85
281	Sexual Function in Untreated and Treated Hypertension. , 2012, , 389-398.		0
282	Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension. International Journal of Hypertension, 2011, 2011, 1-5.	0.5	31
283	Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension. International Journal of Hypertension, 2011, 2011, 1-8.	0.5	26
284	Benefits from Treatment and Control of Patients with Resistant Hypertension. International Journal of Hypertension, 2011, 2011, 1-8.	0.5	20
285	Common Secondary Causes of Resistant Hypertension and Rational for Treatment. International Journal of Hypertension, 2011, 2011, 1-17.	0.5	64
286	Renal sympathetic denervation in hypertension. Current Opinion in Nephrology and Hypertension, 2011, 20, 647-653.	1.0	26
287	Hypertension and sexual dysfunction: time to act. Journal of Hypertension, 2011, 29, 403-407.	0.3	66
288	Tissue factorâ€“thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through upâ€regulation of endothelin receptor A. Arthritis and Rheumatism, 2011, 63, 3586-3597.	6.7	22

#	Article	IF	Citations
289	The multivalent activity of the tissue factorâ€“thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. Expert Opinion on Therapeutic Targets, 2011, 15, 75-89.	1.5	27
290	Renal Sympathetic Denervation: Renal Function Concerns. Hypertension, 2011, 58, e19; author reply e20.	1.3	26
291	Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. Journal of Hypertension, 2010, 28, 2299-2308.	0.3	40
292	Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood, 2010, 116, 631-639.	0.6	124
293	Renal Sympathetic Denervation and Systemic Hypertension. American Journal of Cardiology, 2010, 105, 570-576.	0.7	70
294	Exercise Capacity and Mortality in Older Men. Circulation, 2010, 122, 790-797.	1.6	284
295	Renal sympathetic denervation: the jury is still out. Lancet, The, 2010, 376, 1878-1880.	6.3	42
296	Exercise Capacity and Mortality in Hypertensive Men With and Without Additional Risk Factors. Hypertension, 2009, 53, 494-499.	1.3	107
297	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. Blood Pressure, 2009, 18, 261-267.	0.7	39
298	Exercise Capacity and All-Cause Mortality in Prehypertensive Men. American Journal of Hypertension, 2009, 22, 735-741.	1.0	40
299	Telmisartan for Prevention of Cardiovascular Events. New England Journal of Medicine, 2009, 360, 302-303.	13.9	2
300	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. Blood Pressure, 2009, 18, 261-267.	0.7	3
301	Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control. Expert Opinion on Pharmacotherapy, 2009, 10, 955-966.	0.9	3
302	Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. Expert Opinion on Therapeutic Targets, 2009, 13, 413-425.	1.5	29
303	Interventional management of resistant hypertension. Lancet, The, 2009, 373, 1228-1230.	6.3	30
304	The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease. BMC Cardiovascular Disorders, 2008, 8, 11.	0.7	31
305	Intracerebral Hemorrhage as the Presenting Feature of Concurrent Pheochromocytoma and Paragangliomas. Journal of Clinical Hypertension, 2008, 10, 941-944.	1.0	4
306	Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet, The, 2008, 371, 1921-1926.	6.3	450

#	Article	IF	Citations
307	Pheochromocytoma: ???The Great Mimic???. , 2008, 18, 121-123.		1
308	Sexual dysfunction: the â€˜prima ballerinaâ€™ of hypertension-related quality-of-life complications. Journal of Hypertension, 2008, 26, 2074-2084.	0.3	113
309	Factors Affecting the Increased Prevalence of Erectile Dysfunction in Greek Hypertensive Compared With Normotensive Subjects. Journal of Andrology, 2006, 27, 469-477.	2.0	119
310	The Effect of Antihypertensive Drugs on Erectile Function: A Proposed Management Algorithm. Journal of Clinical Hypertension, 2006, 8, 359-363.	1.0	74
311	Sexual Dysfunction in Essential Hypertension: Myth or Reality?. Journal of Clinical Hypertension, 2006, 8, 269-274.	1.0	40
312	Female sexual dysfunction in essential hypertension: a common problem being uncovered. Journal of Hypertension, 2006, 24, 2387-2392.	0.3	126
313	Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian Journal of Andrology, 2006, 8, 177-182.	0.8	85
314	A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways. Journal of Immunology, 2006, 177, 4794-4802.	0.4	412
315	Microalbuminuria Is Determined by Systolic and Pulse Pressure Over a 12-Year Period and Related to Peripheral Artery Disease in Normotensive and Hypertensive Subjects: The Three Areas Study in Greece (TAS-GR). Angiology, 2006, 57, 313-320.	0.8	12
316	Sibutramine Use Associated with Reversible Hepatotoxicity. Annals of Internal Medicine, 2005, 143, 763.	2.0	10
317	Different Effects of Losartan and Moxonidine on Endothelial Function During Sympathetic Activation in Essential Hypertension. Journal of Clinical Hypertension, 2004, 6, 682-689.	1.0	11
318	Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials; are there any drug differences?. Journal of Diabetes and Metabolic Disorders, 0, , 1.	0.8	0